Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Infinium Pharmachem IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2003 Industry: Chemicals Listed Page

Profile
Issue Size --
Profile
Price Range 135  to  135 per share
Profile
Min Investment ₹135
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Infinium Pharmachem Limited was founded in 2003 and is headquartered in Vadodara, Gujarat. It is an Indian company that specialises in the manufacturing and distribution of fine chemicals, active pharmaceutical ingredients (APIs), and intermediates. Infinium Pharmachem Limited's product portfolio includes a wide range of chemicals used in various industries, including pharmaceuticals, agrochemicals, specialty chemicals, and pigments. The company's APIs and intermediates are used in the treatment of various diseases, including cardiovascular, central nervous system disorders, and cancer. The company has a state-of-the-art manufacturing facility in Vadodara, which is equipped with modern equipment and technology to ensure the highest quality of products. In addition, Infinium Pharmachem Limited has a strong focus on research and development to develop innovative products and processes to meet the needs of its customers. Infinium Pharmachem Limited exports its products to over 30 countries worldwide, including the United States, Europe, and Japan. Read More

Basic Info

Face Value 10 per share

Price 135  to  135 per share

P/E (x) 24.1

Sales( Cr.) 156

PAT( Cr.) 8

EPS 5.6

Draft Prospectus

Exchange NSE-SME

Promoter

Company Promoters

Mr. Sanjaykumar Viththalbhai Patel Mr. Pravin Bhadabhai Madhani Mr. Mitesh Lavjibhai Chikhaliya.

Pre Issue Share Holding 100%

Post Issue Share Holding 73.05%

Listing Details:

Listing Price: 70.75

Listing Gain: -90.81%

Current Price: 213.8

Gain On Issue: 213.8 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Mar 31, 2023
Closing Date Apr 05, 2023
Allotment Apr 06, 2023
Refund Apr 07, 2023
Delivery of Shares Apr 07, 2023
Listing Date Apr 10, 2023

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 1000 135,000
Retail (Max) 1 1000 135,000
S-HNI (Min) 2 2000 270,000
S-HNI (Max) 7 7000 945,000
B-HNI (Min) 8 8000 1,080,000

Objective of the Issue

1. Marketing and branding expenses (including registration in reach - Europe, and other marketing expenses) 2. Repayment of some of the existing loans and expansion of units. 3. To meet incremental working capital requirements. 4. To meet public issue expenses.

Issue

Category Nos Bid Bid (x)
QIB 0 0 0x
NII 0 0 0x
Retail 0 0 0x
EMP 0 0 0x
Total 1875000 3450000 1.8x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Infinium Pharmachem Profit & Loss

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 39 71 99 114 136 156
Other Income 1 1 1 1 2 2
Total Income 39 71 100 116 137 158
Total Expenditure 36 66 89 98 117 139
Operating Profit 3 6 11 17 20 19
Interest 1 1 2 3 2 4
Depreciation 1 1 1 1 3 3
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 1 4 9 13 15 12
Provision for Tax 0 1 2 3 4 4
Profit After Tax 1 3 7 10 12 8
Adjustments 0 -0 -1 -0 -0 0
Profit After Adjustments 1 3 6 9 11 8
Adjusted Earnings Per Share 0.9 2.7 6 9.3 8.1 5.2

Infinium Pharmachem Balance Sheet

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 4 7 13 23 59 109
Minority's Interest 0 0 1 1 1 15
Borrowings 6 6 14 10 8 10
Other Non-Current Liabilities -0 -0 -0 -0 -0 -0
Total Current Liabilities 12 21 31 37 17 64
Total Liabilities 22 34 59 71 85 198
Fixed Assets 4 5 4 19 20 24
Other Non-Current Assets 0 4 11 0 1 34
Total Current Assets 18 25 44 51 65 140
Total Assets 22 34 59 71 85 198

Infinium Pharmachem Cash Flow

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 1 2 5 6 12
Cash Flow from Operating Activities 3 7 12 9 5 -29
Cash Flow from Investing Activities -1 -5 -7 -5 -4 -27
Cash Flow from Financing Activities -1 -1 -2 -3 5 79
Net Cash Inflow / Outflow 1 1 3 1 6 23
Closing Cash & Cash Equivalent 1 2 5 6 12 35

Infinium Pharmachem Ratios

# Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.92 2.68 6.01 9.33 8.12 5.23
CEPS(Rs) 1.43 3.33 7.2 10.97 10.18 7.15
DPS(Rs) 0 0 0 0 0 0
Book NAV/Share(Rs) 4.18 6.91 12.89 22.19 42.24 70.25
Core EBITDA Margin(%) 6.39 7.02 10.12 14.05 13.66 10.58
EBIT Margin(%) 6.38 6.98 10.43 14.06 12.83 9.83
Pre Tax Margin(%) 3.19 5.34 8.71 11.34 11.21 7.43
PAT Margin (%) 2.23 3.87 6.75 8.59 8.48 5.04
Cash Profit Margin (%) 3.73 4.79 7.38 9.77 10.45 7.15
ROA(%) 3.87 9.66 14.37 15.16 14.75 5.53
ROE(%) 20.43 48.44 66.44 55.06 28.28 9.32
ROCE(%) 18.89 32.14 38.88 36.74 28.57 13.23
Receivable days 74.56 50.25 49.49 49.25 48.28 63.52
Inventory Days 64.85 42.14 47.4 57.64 59.75 80.81
Payable days 82.28 62.12 28.25 0 0 0
PER(x) 0 0 0 0 28.2 46.28
Price/Book(x) 0 0 0 0 5.42 3.44
Dividend Yield(%) 0 0 0 0 0 0
EV/Net Sales(x) 0.23 0.14 0.18 0.25 2.34 2.53
EV/Core EBITDA(x) 2.95 1.71 1.65 1.63 15.85 21.19
Net Sales Growth(%) 0 81.58 40.53 15.24 18.76 14.78
EBIT Growth(%) 0 98.82 109.84 55.38 8.37 -12.08
PAT Growth(%) 0 214.58 144.91 46.84 17.17 -31.82
EPS Growth(%) 0 191.73 124.1 55.41 -13 -35.64
Debt/Equity(x) 2.09 1.5 1.72 1.3 0.19 0.47
Current Ratio(x) 1.46 1.2 1.39 1.4 3.73 2.2
Quick Ratio(x) 0.91 0.76 0.87 0.86 2.32 1.5
Interest Cover(x) 2 4.26 6.07 5.17 7.94 4.1
Total Debt/Mcap(x) 0 0 0 0 0.04 0.14

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 15% 16% 32% 0%
Operating Profit CAGR -5% 20% 45% 0%
PAT CAGR -33% 5% 52% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -29% 17% NA% NA%
ROE Average 9% 31% 42% 38%
ROCE Average 13% 26% 30% 28%

Company Contact Information

Infinium Pharmachem Ltd.

Plot No.38 G. I. D. C Sojitra Taluka - Sojitra

IPO Lead Manager(s)

Infinium Pharmachem Ltd.

Swastika Investmart Ltd.

Registrar Info

Infinium Pharmachem Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!